ORDERING INFORMATION

To order PAVBLU™ (aflibercept-ayyh), please refer to the list of distributors below. **PAVBLU™ is available in a single-dose pre-filled plastic syringe or single-dose glass vial.**

PAVBLU™ (aflibercept-ayyh) Injection 2mg

PRODUCT INFORMATION

Product Description	NDC
PAVBLU™ (aflibercept-ayyh) 2 mg/0.05 mL single-dose pre-filled plastic syringe	55513-056-01
PAVBLU™ (aflibercept-ayyh) 2 mg/0.05 mL single-dose glass vial	55513-065-01

DISTRIBUTOR LIST

Contact Information	PAVBLU™ 2 mg/0.05 mL single-dose pre-filled plastic syringe item #	PAVBLU™ 2 mg/0.05 mL single-dose glass vial item #
Besse Medical **Ph: 800.543.2111** besse.com	10293945	10293955
BioCare Specialty Distribution **Ph: 800.304.3064** biocare-us.com	1000974	1000972
Cardinal Health Specialty Hosp/Multi. Specialty **Ph: 855.855.0708 PCP Ph: 877.451.3972** cardinalhealth.com	5951652	5951660
CuraScript Specialty Distribution **Ph: 877.599.7748** curascriptsd.com	10006159	10006158
McKesson Medical Surgical **Ph: 866.625.2679** mms.mckesson.com	1261609	1261607
McKesson Plasma & Biologics **Ph: 877.625.2566** mckesson.com	2994358	2994366
McKesson Specialty Health **Ph: 415.983.8300** mckesson.com	5018905	501906
Metro Medical (Cardinal) **Ph: 800.768.2002** metromedical.com	115601	116501

The specialty distributors identified can fill and distribute PAVBLU™ and are provided herein for informational purposes only and not as an endorsement or recommendation to use any particular pharmacy or distributor over another. This list may not be exhaustive and is subject to change. It represents no statement, promise, or guarantee by Amgen Inc. concerning coverage and/or availability of the product for any particular patient and it is the responsibility of the health care provider to determine the appropriate services provided to their patients.

Please see Indications and **Important Safety Information** and click here for **full Prescribing Information**.

PAVBLU™
(aflibercept-ayyh)
Injection 2mg

INDICATIONS

PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- PAVBLU is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in PAVBLU.

WARNINGS AND PRECAUTIONS

- Intravitreal injections, including those with aflibercept products, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering PAVBLU. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with aflibercept products. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
- The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with aflibercept compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the aflibercept group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with aflibercept compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with aflibercept compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with aflibercept in the first six months of the RVO studies.

ADVERSE REACTIONS

- Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with aflibercept including endophthalmitis and retinal detachment.
- The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
- Patients may experience temporary visual disturbances after an intravitreal injection with PAVBLU and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Please click here for full Prescribing Information for PAVBLU.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please visit **PAVBLU.com** for additional information and resources.

Call **800-77-AMGEN (800-772-6436)** if you have questions about the preparation and administration of PAVBLU™.

Reference: PAVBLU™ (aflibercept) Prescribing Information. Amgen.

PAVBLU™ is not indicated for Retinopathy of Prematurity, for which Regeneron has marketing exclusivity.

AMGEN